Novo Nordisk Symposium

Obesity management is entering a new era. Join for an engaging exploration of current and emerging evidence for semaglutide in obesity care.

This session will review outcomes from the clinical development programme, including weight management, cardiometabolic health and long-term disease risk, alongside clinical experience and recent advances in treatment. The discussion will also examine newer data on alternative formulations and evolving treatment approaches, before looking ahead to the next generation of obesity therapies.

Drawing on perspectives from both specialist and primary care settings, A/Prof Nelson and Dr South will share practical insights on translating evidence into practice. As the therapeutic landscape expands beyond a one-size-fits-all approach, learn how personalised treatment selection, sequencing, patient engagement and long-term management can help optimise outcomes for people living with obesity.